BR112021015616A2 - Ligantes de pseudoquinase tyk2 - Google Patents
Ligantes de pseudoquinase tyk2Info
- Publication number
- BR112021015616A2 BR112021015616A2 BR112021015616A BR112021015616A BR112021015616A2 BR 112021015616 A2 BR112021015616 A2 BR 112021015616A2 BR 112021015616 A BR112021015616 A BR 112021015616A BR 112021015616 A BR112021015616 A BR 112021015616A BR 112021015616 A2 BR112021015616 A2 BR 112021015616A2
- Authority
- BR
- Brazil
- Prior art keywords
- ligands
- tyk2 pseudokinase
- tyk2
- pseudokinase ligands
- disorders
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
ligantes de pseudoquinase tyk2. são descritos no presente documento ligantes de pseudoquinase tyk2 e métodos de utilização de ligantes de pseudoquinase tyk2 no tratamento de doenças, transtornos ou condições. também são descritas no presente documento composições farmacêuticas contendo tais compostos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802642P | 2019-02-07 | 2019-02-07 | |
| PCT/US2020/017314 WO2020163778A1 (en) | 2019-02-07 | 2020-02-07 | Tyk2 pseudokinase ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021015616A2 true BR112021015616A2 (pt) | 2021-11-09 |
Family
ID=71947508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021015616A BR112021015616A2 (pt) | 2019-02-07 | 2020-02-07 | Ligantes de pseudoquinase tyk2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220135567A1 (pt) |
| EP (1) | EP3920931A4 (pt) |
| JP (1) | JP2022519696A (pt) |
| KR (1) | KR20210124409A (pt) |
| CN (1) | CN113677347A (pt) |
| AU (1) | AU2020218267A1 (pt) |
| BR (1) | BR112021015616A2 (pt) |
| CA (1) | CA3129438A1 (pt) |
| IL (1) | IL285429A (pt) |
| MX (1) | MX2021009555A (pt) |
| SG (1) | SG11202108619SA (pt) |
| WO (1) | WO2020163778A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3870579A4 (en) | 2018-10-22 | 2022-10-19 | Alumis Inc. | TYK2 INHIBITORS AND THEIR USES |
| EA202192625A1 (ru) | 2019-03-26 | 2022-03-21 | Вентикс Байосайенсес, Инк. | Лиганды псевдокиназы tyk2 |
| EP4054581A4 (en) | 2019-11-08 | 2023-11-22 | Ventyx Biosciences, Inc. | TYK2 PSEUDOKINASE LIGANDS |
| US20230357273A1 (en) * | 2020-09-16 | 2023-11-09 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
| EP4281458A1 (en) * | 2021-01-19 | 2023-11-29 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Imidazolopyridazine or pyrazolopyrimidine compounds and compositions |
| CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05008955A (es) * | 2003-02-28 | 2006-02-22 | Teijin Pharma Ltd | Derivados de pirazolo [1,5-a] pirimidina. |
| TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| TW202321243A (zh) * | 2017-03-08 | 2023-06-01 | 美商林伯士拉克許米公司 | Ｔｙｋ２抑制劑之生產方法 |
| CN110678467B (zh) * | 2017-05-22 | 2023-06-13 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
| MX2020001103A (es) * | 2017-07-28 | 2020-08-17 | Nimbus Lakshmi Inc | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. |
| JP7179161B2 (ja) * | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| EP3866789A4 (en) * | 2018-10-15 | 2022-07-06 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| TWI800696B (zh) * | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
-
2020
- 2020-02-07 MX MX2021009555A patent/MX2021009555A/es unknown
- 2020-02-07 AU AU2020218267A patent/AU2020218267A1/en active Pending
- 2020-02-07 BR BR112021015616A patent/BR112021015616A2/pt unknown
- 2020-02-07 JP JP2021546005A patent/JP2022519696A/ja active Pending
- 2020-02-07 US US17/428,953 patent/US20220135567A1/en active Pending
- 2020-02-07 EP EP20752194.9A patent/EP3920931A4/en active Pending
- 2020-02-07 CN CN202080026979.3A patent/CN113677347A/zh active Pending
- 2020-02-07 SG SG11202108619SA patent/SG11202108619SA/en unknown
- 2020-02-07 CA CA3129438A patent/CA3129438A1/en active Pending
- 2020-02-07 WO PCT/US2020/017314 patent/WO2020163778A1/en unknown
- 2020-02-07 KR KR1020217028660A patent/KR20210124409A/ko unknown
-
2021
- 2021-08-08 IL IL285429A patent/IL285429A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3920931A4 (en) | 2022-08-10 |
| CA3129438A1 (en) | 2020-08-13 |
| JP2022519696A (ja) | 2022-03-24 |
| EP3920931A1 (en) | 2021-12-15 |
| CN113677347A (zh) | 2021-11-19 |
| SG11202108619SA (en) | 2021-09-29 |
| IL285429A (en) | 2021-09-30 |
| WO2020163778A1 (en) | 2020-08-13 |
| KR20210124409A (ko) | 2021-10-14 |
| AU2020218267A1 (en) | 2021-09-30 |
| US20220135567A1 (en) | 2022-05-05 |
| MX2021009555A (es) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021015616A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
| BR112018012756A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| PH12018501877A1 (en) | Substituted indole mcl-1 inhibitors | |
| BR112022008821A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
| EA202091709A1 (ru) | Ингибиторы днк-пк | |
| BR112019001439A2 (pt) | compostos e composições e usos dos mesmos | |
| BR112021022380A2 (pt) | Inibidores de jak | |
| BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
| EA201891913A1 (ru) | Улучшенные препараты клеток-предшественников взрослой печени | |
| EA202091708A1 (ru) | Ингибиторы днк-пк | |
| MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| MX2020005555A (es) | Construcciones inmunogenicas de peptidos de tau. | |
| ATE475408T1 (de) | Formulierungen von tipifarnib zur intravenösen verabreichung | |
| BR112022018480A2 (pt) | Moduladores de nlrp3 | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| BR112021014566A2 (pt) | Moduladores de gpr35 | |
| BR112022002390A2 (pt) | Inibidores de jak | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ |